<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although treatments for unresectable <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> have made great progress with new anticancer agents, they are still unsatisfactory </plain></SENT>
<SENT sid="1" pm="."><plain>Development of anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy and its management are important in order to improve the treatment outcome of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In the evaluation of treatment effect, obtaining a baseline image at the start of treatment is very important, and CT scan is generally performed for this purpose </plain></SENT>
<SENT sid="3" pm="."><plain>In daily clinical practice, response evaluation criteria in <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>(RECIST)is usually adapted for the assessment of treatment outcomes </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, we should make decisions about continued therapy on the basis of both objective and symptomatic findings </plain></SENT>
<SENT sid="5" pm="."><plain>Patients receiving palliative chemotherapy should be monitored with a CT scan every 2 to 3 months </plain></SENT>
<SENT sid="6" pm="."><plain>It is important to make a treatment strategy individually in consideration of adverse events, purposes of the treatment, and <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> </plain></SENT>
</text></document>